Search

Author/Creator Domchek, S.M.

1. 2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation. (September 2015)

Authors:
Shapira-Frommer, R.; Oza, A.; Domchek, S.M.; Balmana, J.; Patel, M.R.; Chen, L.M.; Drew, Y.; Burris, H.A.; Korach, J.; Flynn, M.; Bowering, V.L.; Morgan, M.A.; Watkins, S.P.; Simpson, D.; Goble, S.; Maloney, L.; Kristeleit, R.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S545
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. (April 2018)

Authors:
Senkus-Konefka, E.; Domchek, S.M.; Im, S.A.; Xu, B.; Armstrong, A.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Conte, P.; Wu, W.; Goessl, C.; Runswick, S.; Robson, M.
Journal:
European journal of cancer
Issue:
Volume 92(2018)Supplement 3
Page Start:
S19
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search